A Phase I Trial of Vorinostat Concurrent With Stereotactic Radiotherapy in Treatment of Brain Metastases From Non-Small Cell Lung Cancer
The purpose of this study is to determine the maximum tolerated dose (MTD) of vorinostat given concurrently with stereotactic radiosurgery (SRS) to treat non-small cell lung cancer (NSCLCA) brain metastases in patient with 1-4 lesions.
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- Joel Neal, MD, PhD
- Steven D. Chang, MD
- Iris C. Gibbs, MD, FACR
- Griffith Harsh, MD
- Scott G. Soltys, MD
- Heather Wakelee, MD
- drug : Vorinostat
- procedure : Radiation Therapy
Phase: Phase 1
Ages Eligible For Study:
- All patients age 18 years and older with histologically proven non-small cell lung cancer and 1-4 brain metastases, each measuring less than 2 cm will be eligible. Prior surgery or radiation is allowed as long as the target metastatic lesion(s) has not been treated with previous radiation. - Adequate organ function (section 3.1.10). - ECOG performance status 0-2. - Life expectancy of >=12 weeks. - Systemic chemotherapy washout period >=7 days.